Table 4 Univariable comparisons of clinical characteristics between patients with hypotension and without hypotension after sequential tapering all vasopressors
Parameter | Hypotension (n = 58) | No hypotension (n = 20) | P value |
|---|---|---|---|
Age | 65 (57 – 72) | 66 (54 – 70) | 0.828 |
Gender, male | 40 (69.0) | 9 (45.0) | 0.056 |
Causes of septic shocka | 0.588 | ||
Pneumonia | 28 (48.3) | 11 (55.0) | |
Intraabdominal infection | 16 (27.6) | 8 (40.0) | |
Urogenital infection | 9 (15.5) | 5 (25.0) | |
Cather related infection | 4 (6.9) | 1 (5.0) | |
Endocarditis | 2 (3.4) | 0 (0.0) | |
Othersb | 3 (5.2) | 0 (0.0) | |
MAP before initial resuscitation, mmHg | 52 (43 – 57) | 52 (50 – 58) | 0.414 |
CVP before initial resuscitation, mmHg | 6 (4 – 8) | 7 (5 – 10) | 0.250 |
MAP at the time of vasopressor initiated, mmHg | 55 (51 – 60) | 54 (50 – 59) | 0.649 |
CVP at the time of vasopressor initiated, mmHg | 11 (9 -14) | 10 (8 – 13) | 0.516 |
Total bilirubin, mg/dL | 1.15 (0.50 – 2.70) | 0.90 (0.60 – 1.83) | 0.406 |
Serum creatinine, mg/dL | 1.42 (0.95 – 2.09) | 1.16 (0.76 – 1.86) | 0.351 |
Lactic acid, mmol/L | 4.19 (2.64 – 6.07) | 3.15 (2.36 – 4.99) | 0.329 |
PCT, ng/mL | 11.81 (2.62 – 34.12) | 15.36 (3.61 – 54.96) | 0.417 |
CRP, mg/mL | 12.60 (5.83 – 21.19) | 20.66 (11.97 – 26.10) | 0.026 |
Maximum NE dose during study period, ug/kg/min | 0.70 (0.50 – 1.31) | 0.40 (0.31 – 1.12) | 0.020 |
SAPS3 | 73 (62 – 74) | 79 (72 – 90) | 0.297 |
SOFA score | 10 (8 – 12) | 10 (8 – 11) | 0.936 |
Clinical status on randomization | |||
MAP, mmHg | 77 (71 – 80) | 76 (68 – 83) | 0.936 |
CVP, mmHg | 10 (8 – 14) | 10 (9 – 13) | 0.606 |
Need for mechanical ventilation | 41 (70.7) | 13 (65.0) | 0.635 |
Need for renal replacement therapy | 18 (31.0) | 4 (20.0) | 0.344 |
Need for dobutamine | 4 (6.9) | 2 (10.0) | 0.643 |
SOFA score | 12 (10 – 15) | 12 (9 – 15) | 0.704 |
PF ratio | 164.9 (99.1 – 267.9) | 164.5 (103.1– 258.5) | 0.972 |
Total bilirubin, mg/dL | 1.40 (0.78 – 3.70) | 1.25 (0.50 – 3.73) | 0.453 |
Serum creatinine, mg/dL | 1.26 (0.74 – 2.10) | 1.01 (0.68 – 1.26) | 0.093 |
Corticosteroid treatment | 52 (94.5) | 20 (100.0) | 0.500 |
Copeptin, pg/mL (n = 76) | 144 (105 – 199) | 223 (109 – 281) | 0.032 |
Time to randomization, hours | 23.3 (12.1 – 44.7) | 24.4 (14.8 – 30.5) | 0.868 |
MAP at the evaluation of outcomes, mmHg | 62 (59 – 63) | 72 (67 – 77) | < 0.001 |
CVP at the evaluation of outcomes, mmHg | 10 (7 – 14) | 10 (8 – 14) | 0.499 |
NE tapering at the evaluation of event outcomes | 46 (79.3) | 11 (55.0) | 0.035 |
AVP tapering at the evaluation of event outcomes | 12 (20.7) | 9 (45.0) | 0.035 |
Total vasopressor duration, hours | 57.8 (39.0 – 110.6) | 30.8 (21.3 – 36.7) | < 0.001 |
Clinical outcomes | |||
ICU mortality | 18 (31.0) | 8 (40.0) | 0.463 |
ICU length of stay, days | 9 (4 – 13) | 7 (3 – 12) | 0.387 |
28-day mortality | 22 (38.6) | 7 (35.0) | 0.775 |
Hospital mortality | 26 (44.8) | 10 (50.0) | 0.689 |
Hospital length of stay, days | 23 (14 – 37) | 19 (14 – 42) | 0.936 |